Clostridium difficile infection is the most common cause of hospital acquired diarrhea and carries significant morbidity and mortality. Current treatment options are limited by high rates of recurrence, and fecal transplantation has proven to be an effective and safe option, with very low rates of recurrence. Multiple mechanisms contribute to the success of this treatment, including prevention of colonization through altering bile salt metabolism and nutrient limitation, antiinflammatory effects, producing bactericidal proteins, and possibly promoting epithelial integrity. This success has lead to increased research in the field of stool-based therapies, which promises greater accessibility, acceptability, and safety than current treatments.
|Title of host publication
|Microbiome and Metabolome in Diagnosis, Therapy, and other Strategic Applications
|Number of pages
|Published - 1 Jan 2019
- Fecal microbial transplantation
- Gastrointestinal infections
- Mucosal immunology